|
Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
| 2022. június 7., kedd 10:00 |
R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics |
|
| Darmstadt, Germany, 7 June, 2022(APA/OTS) - Gaining new market segments in clinical diagnostics - globally unique position as system supplier in laboratory diagnostics sector - R-Biopharm AG, a leading German biotechnology company operating on a global scale, announced the acquisition of AusDiagnostics. R-Biopharm is expanding its product portfolio with the addition of the Australian specialist and manufacturer of molecular biology multiplex diagnostics, extraction reagents, and laboratory automation equipment. The company is thereby unlocking new market segments in clinical diagnostics and continuing on its path of steady internationalization. "The existing and future molecular biology multiplex analysis platforms for syndrome testing from system supplier AusDiagnostics broadens our molecular biology expertise and perfectly complements our present clinical diagnostics portfolio," states Christian Dreher, CEO of R-Biopharm. "The acquisition strengthens our position as a reliable partner for system solutions and offers our customers additional options for diagnostics." |
- Picture is available at AP Images (http://www.apimages.com) -
Upon its establishment in 2006, the Australian company introduced
its patented Multiplex Tandem PCR (MT-PCR) on the market. The
current technology allows the simultaneous detection of up to 24
pathogens or resistance genes from a single sample, thus shortening
the lengthy test procedure in human and animal diagnostics as well
as environmental, agricultural, and food analysis. The analysis
platform is used in laboratories and hospitals throughout the world
for detecting a broad range of diseases.
AusDiagnostics CEO Scott Gilroy said that the transaction marked an
exciting new chapter for the company: "Both AusDiagnostics and
R-Biopharm AG share the same commitment to innovation in the
biotechnology space. This acquisition strengthens AusDiagnostics and
will accelerate our global presence. We've experienced tremendous,
industry-leading growth over the past two years, which has been
underpinned by our broad suite of innovative products, talented
team, and incredible, loyal customers. Joining the R-Biopharm group
will allow us to further build on this and continue to deliver
exceptional products and service for our Australian and
international customers."
AusDiagnostics currently has 92 employees with offices in New
Zealand, the USA, and Great Britain. Its production facilities in
Australia and Great Britain supply a steadily growing network of
more than 25 distributors and partners around the world - from which
R-Biopharm expects further synergy effects for production as well as
international service and support in its clinical diagnostics line.
About R-Biopharm
R-Biopharm AG, located in Darmstadt, is one of Germany's leading
biotechnology companies. It considers itself as a pioneer for health
and quality of life. The company´s aspiration is to provide the
highest possible precision, safety, clarity and certainty with
excellent products and solutions - in prevention, therapy and
healing. Research and development at R-Biopharm has developed agile
processes in order to take on new challenges to accompany a steadily
growing world population into a new health era with sustainable
solutions.
As an internationally recognized leader, R-Biopharm stands for the
development of excellent technologies, products and solutions in the
fields of Clinical Diagnostics, Nutrition Care and Food and Feed
Analytics. R-Biopharm is the global market leader for test systems
in the field of allergen analysis. The biotechnology company is
known for its products that are of high importance for human health.
To this end, it unites development, production and sales under one
roof and is successfully represented in more than 120 countries
worldwide - through 28 subsidiaries and 120 distributors. Founded in
1988, the family-run company employs a total of around 1,300 people
worldwide (690 at its headquarters in Darmstadt) and was repeatedly
recognized with the "Sustainability Award" for sustainable and
profitable growth. R-Biopharm is cultivating a value-oriented
corporate culture and management and is family-run in the second
generation. The Chairman of the Board of Directors is Christian
Dreher.
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/
https://r-biopharm.com/news-press/download-gallery/
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: +49 61 51 - 81 02-538
Mobile: +49 160 - 55 273 60
Fax: +49 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|